Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Lei Nie
Assistant Professor
Lymphoma-Myeloma
https://orcid.org/0000-0001-6969-5013
h-index
2480
Citations
21
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2002
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(33)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Lei Nie is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acquired Resistance
21%
Apoptosis
45%
Basic Helix-loop-helix (bHLH)
27%
BikDD
20%
Breast Cancer Cells
23%
Breast Tumor
23%
Bruton Tyrosine Kinase Inhibitor
35%
Bruton's Tyrosine Kinase
20%
Cancer Cells
21%
Chemotherapy Resistance
21%
Co-target
24%
Constitutively Active
20%
Cyclin-dependent Kinase 2 (CDK2)
60%
Cyclin-dependent Kinase 9 (CDK9)
32%
EIF3D
40%
Enhancer of Zeste Homolog 2 (EZH2)
80%
Epidermal Growth Factor Receptor
43%
Epidermal Growth Factor Receptor Inhibitors
22%
Gasdermin C
40%
Gene Expression
20%
Glutaminase 1 (GLS1)
20%
GRK2
20%
H3K27me3
20%
Hematopoietic Stem Cells
20%
Human Breast Cancer
20%
Ibrutinib
35%
In Cancer
41%
Inhibit Tumor
20%
Inhibitor Resistance
22%
Long ncRNAs
20%
Lymphoma Cells
33%
MALT1
20%
Mantle Cell Lymphoma
100%
MET Inhibitor
20%
NF-B
21%
Overcoming Resistance
24%
PARP Inhibitor (PARPi)
60%
Phosphorylation
26%
Pre-TCR
20%
Pyroptosis
20%
S-phase Kinase-associated Protein 2 (Skp2)
22%
Site-specific Phosphorylation
40%
Spinocerebellar Ataxia
20%
TAL1
20%
Target Molecule
20%
Therapeutic Strategies
21%
Triple-negative Breast Cancer
83%
Tumor Growth
27%
Tumor Necrosis
20%
Ubiquitination
22%
Biochemistry, Genetics and Molecular Biology
ADP-ribosylation
20%
Ankyrin
20%
Ankyrin Repeat
20%
C-Terminus
22%
calcium activated,phospholipid dependent protein kinase
20%
Cancer Cell
68%
Cell Migration
18%
Cell Proliferation
22%
Cyclin-Dependent Kinase
26%
Cyclin-Dependent Kinase 2
20%
Cyclin-Dependent Kinase 9
20%
Deacetylation
20%
Drive
60%
Epidermal Growth Factor Receptor
50%
EZH2
60%
Gene Expression
24%
Glutaminase
20%
Glycogen Synthase Kinase 3
20%
Glycosylation
20%
Green Fluorescent Protein
20%
Growth Factor Receptor Inhibitor
20%
HDAC1
20%
Hematopoietic Cell
20%
Ibrutinib
26%
Immune Evasion
20%
Interleukin 6
20%
Kinase
42%
Long Non-Coding RNA
20%
Methylation
20%
Notch
54%
Notch Signaling Pathway
25%
P-TEFb
20%
PD-L1
20%
Phosphotransferase
42%
Pi3K/Akt Signaling
20%
Poly ADP Ribose Polymerase
40%
Programmed Cell Death
30%
Pyroptosis
20%
Rituximab
20%
STAT5
20%
Stem Cell
20%
T Cell
25%
Targeting Protein
20%
Transcription
32%
Transcription Factor EZH2
40%
Transcription Factor Nrf2
20%
Tyrosine Kinase Inhibitor
25%
Ubiquitin
17%
Ubiquitin Ligase
38%
Ubiquitination
62%
Medicine and Dentistry
Adenosine Diphosphate Ribosylation
20%
BRCA1
10%
Breast Cancer
50%
Bruton Tyrosine Kinase
20%
Bruton Tyrosine Kinase Inhibitor
25%
calcium activated,phospholipid dependent protein kinase
20%
Cancer
20%
Cancer Cell
72%
Caspase 8
10%
Cell Death
20%
Cell Signaling Pathway
20%
Cyclin-Dependent Kinase
26%
Cytotechnology
20%
Diseases
20%
Double-Strand DNA Break
12%
Downregulation
24%
Drive
20%
Epidermal Growth Factor Receptor
40%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Gallbladder Cancer
20%
Glutaminase
20%
Glutamine
10%
Helix Loop Helix Protein
20%
Ibrutinib
36%
In Vitro
9%
Inhibitor of Apoptosis Protein
20%
Lung Cancer
20%
Lymphocyte Development
20%
Mantle Cell Lymphoma
60%
Mantle Cell Lymphoma Cell
35%
Ovarian Cancer
24%
PARP Inhibitor
60%
PARP1
16%
Phosphotransferase
20%
Poly ADP Ribose Polymerase
26%
Programmed Cell Death
62%
Programmed Death-Ligand 1
40%
Pyroptosis
40%
T Cell Acute Lymphocytic Leukemia Protein 1
10%
T Cell Receptor
20%
Talazoparib
10%
Targeting Protein
20%
Thymocyte
14%
Transcription Factor EZH2
20%
Triple Negative Breast Cancer
68%
Tumor Necrosis
40%
Tumor Necrosis Factor
10%
Tyrosine-Kinase Inhibitor
17%
Venetoclax
13%
Xenograft
12%
